Search - tctmd.com

Displaying 181 - 200 of 1554

Sort: Relevancy | Date

Presentation Controversies and Advances 2025

The Good, the Bad and the Ugly of Clinical Trial Design

Presenter: Stuart Pocock

January 31, 2025

Presentation Miami Valves 2025

Clinical Trials for Mitral Regurgitation Beyond TEER: Where to Next

Presenter: Jeffrey Popma

January 30, 2025

Presentation Miami Valves 2025

Clinical Trials Propel TAVR Forward

Presenter: Jeffrey Popma

January 30, 2025

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation TCT 2024

Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis from the IRONMAN II and III Trials

Presenter: Lei Song

October 30, 2024

Presentation TCT 2024

Patient-Reported Outcomes are a True Measure of TTVI Value

Presenter: John Spertus

October 30, 2024

Presentation TCT 2024

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Presenter: Ori Ben-Yehuda

October 30, 2024

Presentation TCT 2024

Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH)

Presenter: Jung-Min Ahn

October 30, 2024

Presentation TCT 2024

Editorial Comments

Presenter: Akiko Maehara

October 30, 2024

Presentation TCT 2024

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

Presenter: Mahesh Madhavan

October 30, 2024

Presentation TCT 2024

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Presenter: Susheel Kodali

October 30, 2024

Presentation TCT 2024

Editorial Comments

Presenter: Vinayak Bapat

October 30, 2024

Presentation TCT 2024

Editorial Comments

Presenter: Neil Fam

October 30, 2024

Presentation TCT 2024

Real World TTVI Registries vs. Randomized Trials: Are the Outcomes Aligned?

Presenter: Brian Whisenant

October 30, 2024

Presentation TCT 2024

Transcatheter Tricuspid Valve Replacement - Lessons Learned From TRISCEND II

Presenter: Charles Davidson

October 30, 2024

Presentation TCT 2024

Editorial Comments

Presenter: Mamas Mamas

October 30, 2024

Presentation TCT 2024

Quantitative Flow Ratio or Fractional Flow Reserve for Guiding Coronary Revascularization

Presenter: Birgitte Krogsgaard Andersen

October 30, 2024

Advertisement

The Good, the Bad and the Ugly of Clinical Trial Design

Clinical Trials for Mitral Regurgitation Beyond TEER: Where to Next

Clinical Trials Propel TAVR Forward

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis from the IRONMAN II and III Trials

Patient-Reported Outcomes are a True Measure of TTVI Value

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH)

Editorial Comments

Late Clinical Outcomes in Small Annulus Patients in the PARTNER Trials

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Editorial Comments

Editorial Comments

Real World TTVI Registries vs. Randomized Trials: Are the Outcomes Aligned?

Transcatheter Tricuspid Valve Replacement - Lessons Learned From TRISCEND II

Editorial Comments

Quantitative Flow Ratio or Fractional Flow Reserve for Guiding Coronary Revascularization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content